🏛️ Verified NIH Record • Updated 2025-06-16
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults (NCT06786520)
A Phase 1 Single Arm, Repeat Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Switching to Cabotegravir Ultra Long-acting From Cabotegravir Long-acting in Healthy Adult Volunteers
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: ViiV Healthcare
🩺 Plain-English Summary (8th-Grade Level)
This study will assess the pharmacokinetics (PK), safety, and tolerability of CAB ULA administered every 4 months (Q4M) following administration of CAB LA every 2 months (Q2M), in healthy adult volunteers.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Mobile, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- GSK Investigational Site — Mobile, Alabama
- GSK Investigational Site — Coral Gables, Florida
- GSK Investigational Site — Oak Brook, Illinois
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in HIV Infections
- Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention — Chicago, Illinois
- The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City — New York, New York
- Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults — Birmingham, Alabama
- Clinical Decision Support for PrEP — Los Angeles, California
- Peer Supported Collaborative Care Mental Health and Substance Use Disorder Care — Baltimore, Maryland
- A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV — Las Vegas, Nevada
Explore by condition: All HIV Infections clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.